Published in Nat Rev Drug Discov on October 01, 2005
Methicillin-resistant Staphylococcus aureus: A public health issue with economic consequences. Can J Infect Dis Med Microbiol (2007) 1.28
Genetics of Streptomyces rimosus, the oxytetracycline producer. Microbiol Mol Biol Rev (2006) 1.15
Genomic analysis of reduced susceptibility to tigecycline in Enterococcus faecium. Antimicrob Agents Chemother (2014) 0.86
Biosensor applications in the field of antibiotic research--a review of recent developments. Sensors (Basel) (2011) 0.86
Synthesis and antibacterial activity of doxycycline neoglycosides. J Nat Prod (2013) 0.81
A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity. PLoS One (2014) 0.80
Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets. Cell Death Differ (2016) 0.78
A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia. Cancer Med (2016) 0.78
The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis. BMC Infect Dis (2016) 0.75
Vorinostat. Nat Rev Drug Discov (2007) 2.83
Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res (2006) 2.58
Abatacept. Nat Rev Drug Discov (2006) 2.13
Pegloticase. Nat Rev Drug Discov (2011) 1.76
Vemurafenib. Nat Rev Drug Discov (2011) 1.68
Tetrabenazine. Nat Rev Drug Discov (2009) 1.60
Eculizumab. Nat Rev Drug Discov (2007) 1.56
Dabigatran etexilate. Nat Rev Drug Discov (2008) 1.41
Sipuleucel-T. Nat Rev Drug Discov (2010) 1.37
Tocilizumab. Nat Rev Drug Discov (2009) 1.36
Effect of decompressive craniectomy on intracranial pressure and cerebrospinal compensation following traumatic brain injury. J Neurosurg (2008) 1.35
Cabazitaxel. Nat Rev Drug Discov (2010) 1.34
Denosumab. Nat Rev Drug Discov (2010) 1.31
Cetuximab. Nat Rev Drug Discov (2004) 1.31
Panitumumab. Nat Rev Drug Discov (2006) 1.31
Everolimus. Nat Rev Drug Discov (2009) 1.29
Liraglutide. Nat Rev Drug Discov (2010) 1.27
Dasatinib. Nat Rev Drug Discov (2006) 1.25
Azacitidine. Nat Rev Drug Discov (2005) 1.23
Enfuvirtide. Nat Rev Drug Discov (2003) 1.22
Daptomycin. Nat Rev Drug Discov (2003) 1.22
Erlotinib hydrochloride. Nat Rev Drug Discov (2005) 1.22
Asenapine. Nat Rev Drug Discov (2009) 1.21
Ipilimumab. Nat Rev Drug Discov (2011) 1.20
Duloxetine hydrochloride. Nat Rev Drug Discov (2004) 1.17
Vismodegib. Nat Rev Drug Discov (2012) 1.16
Oxaliplatin. Nat Rev Drug Discov (2004) 1.14
Eribulin mesylate. Nat Rev Drug Discov (2011) 1.14
Tolvaptan. Nat Rev Drug Discov (2009) 1.13
Febuxostat. Nat Rev Drug Discov (2009) 1.12
Ivacaftor. Nat Rev Drug Discov (2012) 1.12
Golimumab. Nat Rev Drug Discov (2009) 1.11
Lapatinib. Nat Rev Drug Discov (2007) 1.10
Bevacizumab. Nat Rev Drug Discov (2004) 1.09
Lacosamide. Nat Rev Drug Discov (2008) 1.09
Ranibizumab. Nat Rev Drug Discov (2006) 1.08
Sunitinib maleate. Nat Rev Drug Discov (2006) 1.07
Crizotinib. Nat Rev Drug Discov (2011) 1.05
Plerixafor. Nat Rev Drug Discov (2009) 1.04
Brentuximab vedotin. Nat Rev Drug Discov (2012) 1.04
Aflibercept. Nat Rev Drug Discov (2012) 1.04
Exenatide. Nat Rev Drug Discov (2005) 1.02
Pazopanib. Nat Rev Drug Discov (2010) 1.02
Decitabine. Nat Rev Drug Discov (2006) 1.02
Ustekinumab. Nat Rev Drug Discov (2009) 1.02
Varenicline. Nat Rev Drug Discov (2006) 0.99
Gefitinib. Nat Rev Drug Discov (2003) 0.99
Teriparatide. Nat Rev Drug Discov (2003) 0.98
Pregabalin. Nat Rev Drug Discov (2005) 0.98
Certolizumab pegol. Nat Rev Drug Discov (2008) 0.98
Belatacept. Nat Rev Drug Discov (2011) 0.96
Ruxolitinib. Nat Rev Drug Discov (2012) 0.96
Telavancin. Nat Rev Drug Discov (2009) 0.94
Dronedarone. Nat Rev Drug Discov (2009) 0.93
Ezogabine (retigabine). Nat Rev Drug Discov (2011) 0.92
Ecallantide. Nat Rev Drug Discov (2010) 0.91
Posaconazole. Nat Rev Drug Discov (2007) 0.91
Tafamidis. Nat Rev Drug Discov (2012) 0.91
Surgery for brain edema. Neurosurg Focus (2007) 0.91
Pegaptanib sodium. Nat Rev Drug Discov (2005) 0.90
Prasugrel. Nat Rev Drug Discov (2009) 0.90
Memantine hydrochloride. Nat Rev Drug Discov (2004) 0.88
Telbivudine. Nat Rev Drug Discov (2007) 0.87
Fresh from the pipeline. Ticagrelor. Nat Rev Drug Discov (2011) 0.87
Romiplostim. Nat Rev Drug Discov (2008) 0.86
Alvimopan. Nat Rev Drug Discov (2008) 0.86
Sitagliptin. Nat Rev Drug Discov (2007) 0.86
Tipranavir. Nat Rev Drug Discov (2005) 0.85
Velaglucerase alfa. Nat Rev Drug Discov (2010) 0.85
Specificity concerns with antibodies for receptor mapping. Nat Rev Drug Discov (2009) 0.85
Roflumilast. Nat Rev Drug Discov (2010) 0.85
Quadrivalent human papillomavirus recombinant vaccine. Nat Rev Drug Discov (2006) 0.85
Aripiprazole. Nat Rev Drug Discov (2003) 0.84
Pemetrexed disodium. Nat Rev Drug Discov (2004) 0.83
Differential cyclin E expression in human in-stent stenosis smooth muscle cells identifies targets for selective anti-restenosis therapy. Cardiovasc Res (2003) 0.83
Belimumab. Nat Rev Drug Discov (2011) 0.83
Pirfenidone. Nat Rev Drug Discov (2011) 0.83
Pasireotide. Nat Rev Drug Discov (2012) 0.81
Entecavir. Nat Rev Drug Discov (2005) 0.81
Ofatumumab. Nat Rev Drug Discov (2010) 0.81
Efalizumab. Nat Rev Drug Discov (2004) 0.81
Ranolazine. Nat Rev Drug Discov (2006) 0.81
Inhaled aztreonam. Nat Rev Drug Discov (2010) 0.81
Natalizumab. Nat Rev Drug Discov (2005) 0.80
Eplerenone. Nat Rev Drug Discov (2003) 0.80
Meningococcal group A, C, Y and W-135 conjugate vaccine. Nat Rev Drug Discov (2010) 0.80
Abiraterone acetate. Nat Rev Drug Discov (2011) 0.80
Bendamustine. Nat Rev Drug Discov (2008) 0.79
Fresh from the pipeline: Ramelteon. Nat Rev Drug Discov (2005) 0.79
Galsulfase. Nat Rev Drug Discov (2006) 0.78
Rasagiline. Nat Rev Drug Discov (2005) 0.78
Lisdexamfetamine dimesylate. Nat Rev Drug Discov (2007) 0.78
Clofarabine. Nat Rev Drug Discov (2005) 0.78
Omalizumab. Nat Rev Drug Discov (2004) 0.78